We are live on ! Find out more
ATRA icon

Atara Biotherapeutics
ATRA

41 hedge funds and large institutions have $37.1M invested in Atara Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

37% more capital invested

Capital invested by funds: $27M → $37.1M (+$10.1M)

11% more funds holding

Funds holding: 37 → 41 (+4)

1.61% more ownership

Funds ownership: 26.81% → 28.43% (+1.6%)

Holders
41
Holders Change
+4
Holders Change %
+10.81%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
12
Reduced
8
Closed
3
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GC
Globeflex Capital
California
+$922K
2
Marshall Wace
Marshall Wace
United Kingdom
+$490K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$336K
4
BCM
Bridgeway Capital Management
Texas
+$279K
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$273K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$376K
2
Morgan Stanley
Morgan Stanley
New York
-$298K
3
UBS Group
UBS Group
Switzerland
-$237K
4
Jane Street
Jane Street
New York
-$120K
5
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
-$76.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$181K +$150K +10,028 New
TRCT
27
Tower Research Capital (TRC)
New York
$31.4K +$20.8K +1,395 +408%
SS
28
SBI Securities
Japan
$25.4K – – –
UBS Group
29
UBS Group
Switzerland
$25.3K -$237K -15,871 -92%
PWAM
30
Private Wealth Asset Management
Iowa
$16.3K – – –
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$15K -$5.36K -359 -30%
Jones Financial Companies
32
Jones Financial Companies
Missouri
$12.7K – – –
Wells Fargo
33
Wells Fargo
California
$4.54K – – –
JP Morgan Chase
34
JP Morgan Chase
New York
$3.91K – – –
BT
35
Banque Transatlantique
France
$3.18K – – –
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$3.17K – – –
Federated Hermes
37
Federated Hermes
Pennsylvania
$2.35K +$1.94K +130 New
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$832 -$60 -4 -8%
Osaic Holdings
39
Osaic Holdings
Arizona
$180 – – –
Rockefeller Capital Management
40
Rockefeller Capital Management
New York
$145 – – –
KFP
41
Kerr Financial Planning
California
$112 – – –
GCP
42
GSA Capital Partners
United Kingdom
– -$376K -26,213 Closed
Group One Trading
43
Group One Trading
Illinois
– -$2.12K -148 Closed
AIP
44
Alexis Investment Partners
Texas
– -$215 -15 Closed
1
2

ATRA Hedge Fund Activity: Q4 2025 in Review

41 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2025, worth a combined $37.1M — up 37% from $27M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ATRA positions and 3 closed out — a net gain of 4 holders — while 12 added to existing stakes and 8 trimmed.

The largest buyer was Globeflex Capital, adding an estimated $922K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $376K sold.

  • 41 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2025, up from 37 in Q3 2025.
  • Funds reported $37.1M of Atara Biotherapeutics stock for Q4 2025, up 37% quarter-over-quarter.
  • 7 funds opened new Atara Biotherapeutics positions in Q4 2025 and 3 closed out, a net change of +4 holders.
  • The largest Atara Biotherapeutics buyer in Q4 2025 was Globeflex Capital, an estimated $922K added.
  • The largest Atara Biotherapeutics seller in Q4 2025 was GSA Capital Partners, an estimated $376K sold.

Based on aggregated 13F filings for Q4 2025.